tailieunhanh - Báo cáo sinh học: " Tumor escape and progression of HER-2/neu negative breast cancer under immune pressure"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành hóa học dành cho các bạn yêu hóa học tham khảo đề tài: Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành hóa học dành cho các bạn yêu hóa học tham khảo đề tài: Tumor escape and progression of HER-2/neu negative breast cancer under immune pressure | Kmieciak et al. Journal of Translational Medicine 2011 9 35 http content 9 1 35 TRANSLATIONAL MEDICINE RESEARCH Open Access Tumor escape and progression of HER-2 neu negative breast cancer under immune pressure 11 2 2 3 4 Maciej Kmieciak Kyle K Payne Michael O Idowu Margaret M Grimes Laura Graham Maria-Libera Ascierto Ena Wang4 Xiang-Yang Wang5 Harry D Bear3 and Masoud H Manjili1 Abstract Background Emerging data from pre-clinical and clinical studies suggest that HER-2 neu-specific T cell responses could induce HER-2 neu antigen loss in the tumor cells. These data suggest that patients with HER-2 neu negative breast cancer might have had HER-2 neu positive premalignant lesions in the past that progressed to HER-2 neu negative breast cancer under HER-2 neu-specific immune pressure. Methods We conducted a pilot study in patients with HER-2 neu positive and HER-2 neu negative breast cancers as well as a patient with ductal carcinoma in situ DCIS . HER-2 neu expression was determined by FISH. HER-2 neu-specific T cell responses were determined by using IFN-y ELISA. Expression of IFN-y Ra in the tumors was determined by immunohistochemistry analysis of paraffin-embedded tissues. Results We determined that majority of 10 of 12 patients with HER-2 neu negative breast cancer had HER-2 neu-specific IFN-y producing T cell responses which was stronger than those in patients with HER-2 neu positive tumors. Such immune responses were associated with nuclear translocation of IFN-y Ra in their tumor cells. Patient with DCIS also showed HER-2 neu-specific T cell responses. Conclusion These data suggest that conducting retrospective studies in patients with HER-2 neu negative breast cancers and prospective studies in patients with HER-2 neu positive DCIS can determine whether HER-2 neu negative invasive carcinomas arise from HER-2 neu positive DCIS under the immune pressure. Introduction In recent years there has been emerging evidence from both .

TÀI LIỆU LIÊN QUAN
TÀI LIỆU MỚI ĐĂNG
8    188    0    15-05-2024
10    167    0    15-05-2024
37    166    0    15-05-2024
10    123    0    15-05-2024
173    110    0    15-05-2024
28    118    0    15-05-2024
crossorigin="anonymous">
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.